[Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma] (original) (raw)

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014

Abstract

A prospective, multicenter and non-interventional prospective study was conducted to evaluate the clinical features of rituximab combined with chemotherapy (R-Chemo) as first-line treatment on newly diagnosed Chinese patients with diffuse large B-cell lymphoma (DLBCL). This was a single arm, prospective, observational multicenter and phase IV clinical trial for 279 patients, who were newly diagnosed as CD20-positive DLBCL from 24 medical centers in China 2011 and 2012, no special exclusion criteria were used. All patients received rituximab based R-Chemo regimes, such as R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone) and other regimes as the first-line treatment. The treatment strategies were determined by physicians and patients without detailed description for treatment course, dose, interval time and examination. Clinical response and safety of all patients were investigated in 120 days after completion of last dose of rituximab. Of 279 patien...

Mingzhi Zhang hasn't uploaded this paper.

Let Mingzhi know you want this paper to be uploaded.

Ask for this paper to be uploaded.